中高危患者经导管与外科主动脉瓣置换的荟萃分析
结果显示两者早期和晚期死亡率及卒中风险无差异,TAVR减少大出血和急性肾损伤但增加起搏器植入、血管并发症和残余主动脉瓣反流。
要点
- 中高危患者TAVR与SAVR的早期和晚期死亡率及卒中风险相似。
- TAVR降低大出血和急性肾损伤风险,但增加起搏器植入和血管并发症。
- TAVR后残余主动脉瓣反流更常见,SAVR瓣膜跨瓣压差较差。
核心结论
- 中高危患者TAVR与SAVR的短期和长期全因死亡率及卒中风险相似。
- TAVR降低大出血和急性肾损伤风险并改善血流动力学,但增加血管并发症、起搏器需求和残余主动脉瓣反流。
研究设计与样本
- 荟萃分析纳入倾向性评分匹配研究或随机临床试验,比较中高危患者TAVR与SAVR的主要不良结局。
- 采用随机效应模型计算合并OR、相对风险或均数差及95%CI,并进行了敏感性和发表偏倚分析。
主要发现
- 早期死亡率无差异(OR=1.11,95%CI 0.9-1.39,P=0.355),晚期死亡率无差异(相对风险=0.91,95%CI 0.78-1.05,P=0.194)。
- TAVR与大出血风险降低相关(OR=0.42,95%CI 0.25-0.69,P<0.001)和急性肾损伤风险降低相关(OR=0.51,95%CI 0.34-0.71)。
- TAVR与起搏器植入增加相关(OR=2.31,95%CI 1.73-3.08)和血管并发症增加相关(OR=4.88,95%CI 2.84-8.39)。
- TAVR后残余主动脉瓣反流更常见(OR=6.83,95%CI 4.87-9.6)。
- SAVR瓣膜跨瓣压差较差(均数差:-2.4 mmHg,95%CI -3.27至-1.53)。
临床怎么用
- 中高危主动脉瓣病变患者选择TAVR或SAVR时,应综合评估出血、肾损伤、起搏器植入、血管并发症和残余反流风险。
- TAVR可考虑用于出血或肾损伤风险较高的患者,但需警惕起搏器植入和血管并发症。
- SAVR可考虑用于血管条件差或残余反流风险高的患者,但需注意瓣膜跨瓣压差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The evidence of the benefits of transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for patients of high or intermediate surgical risk is not consistent. We performed a meta-analysis to compare major adverse outcomes after TAVR or SAVR. METHODS: We searched propensity score matched studies or randomized clinical trials comparing the risks of mortality, stroke, major bleeding, acute renal injury, pacemaker implantation, vascular complications and prostheses haemodynamic performance between TAVR and SAVR in patients with moderate or high risk. Combined odds ratios (ORs), relative risk or mean differences with corresponding 95% confidence intervals (CIs) were calculated using a random effects model. Analyses of sensitivity and publication bias were also conducted. RESULTS: We included 5 clinical trials and 37 observational studies, enrolling 20 224 patients (TAVR, n = 9099 and SAVR, n = 11 125). The pooled analysis suggested no differences in early (OR = 1.11, 95% CI 0.9-1.39, P = 0.355) or late mortality (relative risk = 0.91, 95% CI 0.78-1.05, P = 0.194). TAVR was associated with a lower risk of major bleeding (OR = 0.42, 95% CI 0.25-0.69, P < 0.001) and acute kidney injury (OR = 0.51, 95% CI 0.34-0.71) but with an increase in the incidence of pacemaker implantation (OR = 2.31, 95% CI 1.73-3.08) and vascular complications (OR = 4.88, 95% CI 2.84-8.39). Residual aortic regurgitation was more frequent after TAVR (OR= 6.83, 95% CI 4.87-9.6). SAVR prostheses were associated with poor trans-prosthetic gradients (mean difference: -2.4 mmHg, 95% CI - 3.27 to - 1.53). CONCLUSIONS: TAVR and SAVR have similar short and long-term all-cause mortality and risk of stroke among patients of moderate or high surgical risk. TAVR decreases the risk of major bleeding, acute kidney injury and improves haemodynamic performance compared with SAVR but increases the risk of vascular complications, the need for a pacemaker and residual aortic regurgitation.
引用
- Carnero-Alcázar M, Maroto LC, Cobiella-Carnicer J, et al. Transcatheter versus surgical aortic valve replacement in moderate and high-risk patients: a meta-analysis. Eur J Cardiothorac Surg. 2017. PMID: 28007879. doi:10.1093/ejcts/ezw388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。